Cantor Fitzgerald Expects Stronger Earnings for Immunocore

Immunocore Holdings plc (NASDAQ:IMCR) – Investment analysts at Cantor Fitzgerald increased their FY2025 EPS estimates for Immunocore in a research note issued to investors on Thursday, February 27th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will post earnings per share of ($1.42) for the year, up from their previous estimate of ($2.33). The consensus estimate for Immunocore’s current full-year earnings is ($0.94) per share.

Several other equities analysts have also issued reports on the stock. Needham & Company LLC reiterated a “buy” rating and set a $71.00 target price on shares of Immunocore in a report on Thursday, February 27th. Mizuho lowered shares of Immunocore from an “outperform” rating to a “neutral” rating and lowered their target price for the company from $72.00 to $38.00 in a report on Monday, November 11th. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 target price (down from $74.00) on shares of Immunocore in a report on Friday, December 13th. Finally, HC Wainwright restated a “buy” rating and issued a $100.00 price objective on shares of Immunocore in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $65.64.

Immunocore Price Performance

IMCR stock opened at $29.25 on Monday. The firm has a 50 day moving average price of $30.10 and a 200-day moving average price of $31.71. Immunocore has a 52-week low of $27.69 and a 52-week high of $67.30. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of -30.79 and a beta of 0.77. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78.

Hedge Funds Weigh In On Immunocore

A number of hedge funds have recently added to or reduced their stakes in IMCR. Primecap Management Co. CA lifted its holdings in shares of Immunocore by 26.7% during the 3rd quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after buying an additional 520,950 shares during the period. State Street Corp lifted its holdings in shares of Immunocore by 63.9% during the 3rd quarter. State Street Corp now owns 76,671 shares of the company’s stock valued at $2,387,000 after buying an additional 29,897 shares during the period. Principal Financial Group Inc. boosted its position in Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company’s stock worth $17,007,000 after purchasing an additional 109,206 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Immunocore by 125.4% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company’s stock worth $1,463,000 after purchasing an additional 27,598 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Immunocore by 7,437.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 92,257 shares of the company’s stock valued at $2,872,000 after purchasing an additional 91,033 shares during the period. 84.50% of the stock is currently owned by hedge funds and other institutional investors.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.